Group 1: Company Overview - Zhuhai Tainomai Bo Pharmaceutical Co., Ltd. (Tainomai Bo) has submitted its IPO application, marking a significant step for the fifth listing standard on the Sci-Tech Innovation Board [1] - The company was established in 2015 and its core product, Staitouta Monoclonal Antibody Injection (New Taituo), is the world's first recombinant anti-tetanus toxin monoclonal antibody drug [2] - Staitouta is recognized as a breakthrough therapy and has been included in the priority review process by the Chinese drug regulatory authority [2] Group 2: Product Details - Staitouta is expected to reduce reliance on human blood products for passive immunity against tetanus, with approval for sale in China anticipated by February 2025 [3] - The drug addresses a significant public health threat, as tetanus has a mortality rate close to 100% without medical intervention and remains high even with modern medical care [3] - Traditional passive immunization methods require complex procedures, while Staitouta offers a simplified administration process [4] Group 3: Financial Performance - Despite the product's potential, Tainomai Bo's revenue remains limited, with reported revenues of 4.34 million RMB in 2022, 0 in 2023, and 1.51 million RMB in 2024, with only 16,930 RMB in Q1 2025 [5] - The company has incurred significant losses, with net profits of approximately -4.29 billion RMB in 2022 and -1.77 billion RMB in Q1 2025, leading to a cumulative loss of 1.02 billion RMB by March 2025 [5] Group 4: Market Position and Competition - Tainomai Bo's pricing strategy for Staitouta is a concern, as it lacks a competitive edge compared to tetanus human immunoglobulin, which is covered by medical insurance and has significantly lower prices [6][8] - The company is developing multiple antibody candidates to mitigate reliance on a single product, including TNM001, which is in Phase III clinical trials [9] Group 5: Industry Trends - The introduction of the fifth listing standard on the Sci-Tech Innovation Board is expected to attract more companies, including those outside the biopharmaceutical sector [10] - The market for RSV treatments is projected to reach $12.8 billion globally by 2030, indicating a competitive landscape for Tainomai Bo's products [9] - Other non-pharmaceutical companies are also preparing to apply for the fifth listing standard, indicating a growing interest in diverse sectors [11][12]

Group 1 - The core point of the article is that Zhuhai Tenomab Pharmaceutical Co., Ltd. has become the first company to apply the professional institutional investor system in the Sci-Tech Innovation Board IPO process, which aims to enhance the identification of technology-driven enterprises and their investment value [1][2] - The introduction of the professional institutional investor system is intended to leverage the insights of leading venture capital and industry funds to improve the efficiency of capital market resource allocation [1] - Tenomab's disclosure of a professional institutional investor that acquired 3.94% of its shares prior to the IPO indicates a positive signal for the company, which is currently in a loss-making phase [1] Group 2 - The professional institutional investor system is a well-established practice in foreign markets, such as the Hong Kong Stock Exchange's rules regarding "professional investors" [2] - Unlike foreign markets, the reform in the Sci-Tech Innovation Board is a pilot program limited to companies under the fifth listing standard, ensuring flexibility and exploration without imposing unnecessary barriers to listing [2] - Regulatory authorities have detailed the criteria for recognizing professional institutional investors based on investment experience and holding duration, which helps prevent sudden share acquisitions and ensures the system's rigor and standardization [2]

Group 1 - The core viewpoint of the news is that Zhuhai Tenomab Pharmaceutical Co., Ltd. has become the first company to apply for an IPO under the new system for qualified institutional investors on the Sci-Tech Innovation Board, which aims to enhance the identification of technology-driven enterprises and their commercial prospects [1][2] - The introduction of the qualified institutional investor system is intended to leverage the insights of leading venture capital and industry funds to improve the efficiency of resource allocation in the capital market [1][2] - Tenomab disclosed that a qualified institutional investor acquired 3.94% of its shares within 24 months prior to the IPO application, which is seen as a positive indicator for the company, especially as it is still in a loss-making phase [1] Group 2 - The qualified institutional investor system is a well-established practice in foreign markets, such as the Hong Kong Stock Exchange, which includes specific regulations for "qualified investors" [2] - Unlike foreign markets, the reform on the Sci-Tech Innovation Board is a pilot program limited to companies under the fifth set of listing standards, ensuring flexibility and exploration without imposing unnecessary barriers to listing [2] - Regulatory authorities have detailed criteria for identifying qualified institutional investors based on investment experience, holding period, and other factors, which helps prevent sudden stock acquisitions and ensures the system's rigor and standardization [2]

Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. has received approval for its IPO application on the Sci-Tech Innovation Board, marking it as the first company to apply under the newly reintroduced fifth listing standard for unprofitable enterprises since June 18, 2023 [1][2] Company Overview - Tainuo Maibo was established in 2015 and is an innovative biopharmaceutical company focused on developing novel drugs [1] - The company's core product, Staitouta Monoclonal Antibody Injection (New Timo®), is expected to be approved for sale in China by February 2025, representing a significant innovation in the field of tetanus prevention [1] - Another key product, TNM001, is a long-acting monoclonal antibody for the prevention of RSV in healthy and high-risk infants, currently undergoing Phase III clinical trials [1] Financial Performance - The company's main business revenues for 2022-2024 and Q1 2025 were 330,000 yuan, 0 yuan, 15 million yuan, and 169,300 yuan respectively [2] - Net losses during the same period were 429 million yuan, 446 million yuan, 515 million yuan, and 177 million yuan [2] - R&D expenses for the same years were 323 million yuan, 393 million yuan, 425 million yuan, and 134 million yuan [2] - The company has not yet generated revenue from its main products, relying instead on patent technology transfer income [2] IPO Fundraising Plans - Tainuo Maibo aims to raise 1.5 billion yuan through its IPO, with allocations of 830 million yuan for new drug R&D, 330 million yuan for expanding antibody production facilities, and 340 million yuan for working capital [1] Industry Context - As of August 1, 2023, a total of 38 companies have applied for listing under the fifth standard, with 20 successfully listed and 12 withdrawing their applications [3] - Other companies that have passed the review under this standard include He Yuan Bio and Bei Xin Life, both from the biopharmaceutical sector [3] - Three additional companies are currently in the queue for IPO under the fifth standard, with varying stages of review [3]

【导读】泰诺麦博IPO申请获受理，采用科创板第五套标准 7月31日晚，据上交所网站披露，珠海泰诺麦博制药股份有限公司（以下简称泰诺麦博）科创板上市申请获受理。泰诺麦博采用科创板第五套标准上市， 保荐机构是华泰证券。 科创板第五套标准重启 此次泰诺麦博的受理，可以说是真正迎来"新鲜血液"。招股书中，公司自述是一家面向全球市场、致力于血液制品替代疗法的创新生物制药企业，目前已 开发出"全球同类首创（First-in-Class）的斯泰度塔单抗注射液"。 7月1日，同样采用该套标准上市的禾元生物，成为首家重启后获上市委会议通过的企业，并在7月4日提交注册，7月18日注册生效。禾元生物之后，同样 采用科创板第五套标准的北芯生命，也很快提交注册并生效。 根据《上海证券交易所科创板股票上市规则》，科创板第五套标准为："预计市值不低于人民币40亿元，主要业务或产品需经国家有关部门批准，市场空 间大，目前已取得阶段性成果。医药行业企业需至少有一项核心产品获准开展二期临床试验，其他符合科创板定位的企业需具备明显的技术优势并满足相 应条件。"这是科创板五套上市标准中唯一对营业收入不做要求的。 记者注意到，从科创板2019年7月开 ...

Core Viewpoint - The IPO application of Zhuhai Tainomai Bo Pharmaceutical Co., Ltd. has been accepted, marking it as the first company to utilize the fifth set of standards for the Sci-Tech Innovation Board since its restart on June 18, 2025 [2][5]. Group 1: IPO Details - Tainomai Bo's IPO application was accepted on July 31, 2025, with Huatai Securities as the sponsor [2][3]. - The company plans to raise 1.5 billion RMB for new drug research and development, expansion of antibody production facilities, and to supplement working capital [12][13]. Group 2: Company Background - Tainomai Bo is an innovative biopharmaceutical company focused on global markets, specializing in blood product alternatives [8]. - The company has developed the "First-in-Class" Staitouta monoclonal antibody injection, recognized as a breakthrough treatment drug in the anti-infection field [9]. Group 3: Financial Performance - The company reported minimal revenue, with the Staitouta monoclonal antibody injection expected to generate sales starting in March 2025 [9]. - Tainomai Bo has incurred continuous net losses, with cumulative losses reaching 1.024 billion RMB by the end of the reporting period [11].

Core Viewpoint - Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. has officially submitted its IPO application to the Shanghai Stock Exchange, marking the first acceptance under the newly restarted fifth listing standard for the Sci-Tech Innovation Board [1] Group 1: Company Overview - Tainuo Maibo, established in 2015, is an innovative biopharmaceutical company focused on the development of innovative biological drugs [2] - The company reported revenues of 4.34 million yuan, 0 yuan, 15.06 million yuan, and 169,300 yuan for the years 2022 to the first quarter of 2025, with net losses of 429 million yuan, 446 million yuan, 515 million yuan, and 177 million yuan during the same period [2] Group 2: IPO Details - The company aims to raise 1.5 billion yuan through its IPO, which will be allocated to new drug research and development, expansion of antibody production facilities, and supplementing working capital [1] - Huatai United Securities is the sponsor for this IPO [1] Group 3: Market Context - The acceptance of Tainuo Maibo's application further validates the practicality of the fifth listing standard, which is designed for unprofitable companies with certain revenue scales, providing a pathway for innovative drug companies in their early commercialization stages [1] - The "1+6" new policy introduced on June 18 supports high-quality unprofitable technology companies in going public, including the reintroduction of the fifth listing standard and the expansion of its applicability [1]

Group 1 - The core point of the article is the acceptance of Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd.'s IPO application under the Sci-Tech Innovation Board, marking a significant milestone for companies meeting the fifth listing standard [1][2]. - Tainuo Maibo's IPO is based on the fifth listing standard, which requires a minimum market value of 4 billion yuan and approval for core products from relevant authorities [2][3]. - The company has reported minimal revenue from technology transfer, with losses exceeding 1.4 billion yuan over three years, but its core product "New Tizhuo" has been approved for commercialization [3][4]. Group 2 - "New Tizhuo" is the world's first recombinant monoclonal antibody drug for emergency prevention of tetanus after exposure to trauma, which could reduce reliance on human blood-derived products [4][5]. - The scarcity of blood products in China, due to regulatory restrictions since 2001, enhances the commercial prospects for "New Tizhuo" [6]. - Tainuo Maibo's IPO fundraising plan allocates 340 million yuan for working capital, significantly higher than similar projects, indicating a positive signal for the innovative medical industry [7].

Core Insights - The IPO application of Zhuhai Tainuo Maibo Pharmaceutical Co., Ltd. has been accepted, marking it as the first company to be accepted under the restarted fifth listing standard of the Sci-Tech Innovation Board [1] - The company aims to raise 1.5 billion yuan through its IPO [1] - Tainuo Maibo has been recognized as a company focused on innovative biopharmaceutical development, with a significant emphasis on long-term R&D projects [2] Financial Performance - The company's revenue from 2022 to Q1 2025 is reported as 4.34 million yuan, 0 yuan, 15.06 million yuan, and 169,300 yuan respectively [1] - The net losses during the same period are 429 million yuan, 446 million yuan, 515 million yuan, and 177 million yuan respectively [1] Investment and Partnerships - Tainuo Maibo has received investment from Zhuhai Hillhouse Private Equity Fund Management Co., Ltd., which is recognized as a qualified institutional investor [2] - Hillhouse Capital, the parent company of Zhuhai Hillhouse, has a track record of investing in over five technology companies that have listed on the Sci-Tech Innovation Board in the past five years [2] Regulatory Framework - The acceptance of Tainuo Maibo's IPO is part of the implementation of new policies aimed at enhancing the inclusivity of the Sci-Tech Innovation Board for high-quality, unprofitable technology companies [1] - The new policies include the establishment of a growth tier and the introduction of qualified institutional investors [1][3]

Group 1 - The core viewpoint of the news is that Tianomab has become the first company to be accepted under the fifth listing standard of the Sci-Tech Innovation Board after its resumption, indicating a significant step in the inclusion of unprofitable companies in the market [2] - Tianomab has received investment from seasoned professional institutional investors, specifically from Zhuhai Hillhouse Private Equity Fund Management Co., Ltd., which has been a shareholder since May 2021 [3] - The company has developed several antibody drugs, with its flagship product, Staidotamab injection, already approved for market launch, and other candidates in various stages of clinical trials [4] Group 2 - Tianomab was established in 2015 and is recognized as an innovative biopharmaceutical company, focusing on the development of antibody drugs [4] - The company plans to raise 1.5 billion yuan through its IPO, with the funds allocated for new drug research and development, expansion of antibody production facilities, and supplementing working capital [4] - From 2022 to 2024, the company is expected to invest over 1.1 billion yuan in research and development [4]